FDA OK’s Diabetic Neuropathy Capsaicin Patch; EDCs Still a Threat
The FDA approved an 8% capsaicin patch (Qutenza) for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults, Grünenthal and Averitas Pharma announced.
During the pandemic, kids and teens with newly diagnosed type 1 diabetes saw an uptick in diabetic ketoacidosis and severe ketoacidosis, a German study found. “Underlying causes may be multifactorial and reflect reduced medical services, fear of approaching the health care system, and more complex psychosocial factors,” the group wrote in JAMA.
And in a study of 433 COVID-19 patients in France, about 25% had diabetes. This was not, however, tied to a greater odds of ICU admission nor mortality. (Diabetes Metabolism Research & Reviews)
A group of researchers made a plea for economic, regulatory, and policy approaches to tackle the ever-growing threat of endocrine-disrupting chemicals. “Our understanding of endocrine disruptors has evolved, but the regulations in place to protect against them have not,” said senior author Leonardo Trasande, MD, of NYU Langone. (The Lancet Diabetes and Endocrinology)
Could menopausal hormone therapy help stave off urinary tract infections? (Everyday Health)
In a large study of young adult patients, recombinant human growth hormone treatment during childhood was not tied to any increased all-cause mortality. However, cause-specific mortality from diseases of the circulatory and hematological systems was elevated. (The Lancet Diabetes and Endocrinology)
Less-than-stellar gut microbiome: another potential risk factor for type 1 diabetes?